Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1953 4
1954 1
1955 1
1956 2
1957 5
1958 3
1959 2
1961 1
1962 1
1963 3
1964 5
1965 8
1966 6
1967 7
1968 13
1969 9
1970 17
1971 17
1972 16
1973 17
1974 16
1975 14
1976 10
1977 11
1978 21
1979 31
1980 25
1981 27
1982 42
1983 24
1984 43
1985 47
1986 36
1987 38
1988 43
1989 44
1990 54
1991 45
1992 51
1993 39
1994 42
1995 38
1996 35
1997 41
1998 45
1999 18
2000 45
2001 39
2002 43
2003 41
2004 36
2005 43
2006 55
2007 35
2008 47
2009 47
2010 43
2011 41
2012 39
2013 43
2014 32
2015 28
2016 42
2017 34
2018 30
2019 36
2020 28
2021 30
2022 21
2023 16
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

1,825 results

Results by year

Filters applied: . Clear all
Page 1
Factors Affecting Gastrointestinal Absorption of Levothyroxine: A Review.
Skelin M, Lucijanić T, Amidžić Klarić D, Rešić A, Bakula M, Liberati-Čizmek AM, Gharib H, Rahelić D. Skelin M, et al. Clin Ther. 2017 Feb;39(2):378-403. doi: 10.1016/j.clinthera.2017.01.005. Epub 2017 Jan 30. Clin Ther. 2017. PMID: 28153426 Review.
PURPOSE: Levothyroxine (LT4) is a drug with a narrow therapeutic index, applied in small amounts (micrograms), which makes interactions in the absorption phase clinically significant. ...METHODS: Relevant data were collected by using the MEDLINE, PubMed, EMBASE, Web of Sci …
PURPOSE: Levothyroxine (LT4) is a drug with a narrow therapeutic index, applied in small amounts (micrograms), which makes interactio …
Levothyroxine Therapy in Gastric Malabsorptive Disorders.
Virili C, Brusca N, Capriello S, Centanni M. Virili C, et al. Front Endocrinol (Lausanne). 2021 Jan 28;11:621616. doi: 10.3389/fendo.2020.621616. eCollection 2020. Front Endocrinol (Lausanne). 2021. PMID: 33584549 Free PMC article. Review.
Oral levothyroxine sodium is absorbed in the small intestine, mainly in the jejunum and the ileum being lower the absorption rate at duodenal level. ...However, several evidence confirm the key role of the stomach as a prerequisite for an efficient absorption of oral le …
Oral levothyroxine sodium is absorbed in the small intestine, mainly in the jejunum and the ileum being lower the absorption rate at …
The emergence of levothyroxine as a treatment for hypothyroidism.
Hennessey JV. Hennessey JV. Endocrine. 2017 Jan;55(1):6-18. doi: 10.1007/s12020-016-1199-8. Epub 2016 Dec 16. Endocrine. 2017. PMID: 27981511 Review.
METHODS: A Medline search was initiated using the search terms, levothyroxine, thyroid hormone history, levothyroxine mono therapy, thyroid hormone replacement, combination LT4 therapy, levothyroxine Bioequivalence. ...Levothyroxine mono-therapy has em …
METHODS: A Medline search was initiated using the search terms, levothyroxine, thyroid hormone history, levothyroxine mono the …
Pharmacokinetics and Comparative Bioavailability of a Levothyroxine Sodium Oral Solution and Soft Capsule.
Tanguay M, Girard J, Scarsi C, Mautone G, Larouche R. Tanguay M, et al. Clin Pharmacol Drug Dev. 2019 May;8(4):521-528. doi: 10.1002/cpdd.608. Epub 2018 Aug 28. Clin Pharmacol Drug Dev. 2019. PMID: 30153382 Free PMC article. Clinical Trial.
A study has been conducted to compare the bioavailability of levothyroxine sodium oral solution and levothyroxine sodium soft capsule in healthy volunteers under fasting conditions. ...In conclusion, levothyroxine oral solution unit-dose ampules were bioequiv …
A study has been conducted to compare the bioavailability of levothyroxine sodium oral solution and levothyroxine sodium soft …
No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects.
Huang F, Ajavon A, Huang E, Lettieri J, Liu R, Peña C, Berse M. Huang F, et al. Thyroid. 2017 Sep;27(9):1118-1127. doi: 10.1089/thy.2017.0085. Epub 2017 Aug 29. Thyroid. 2017. PMID: 28741453 Free PMC article. Clinical Trial.
This study assessed sorafenib pharmacokinetics without and with concomitant levothyroxine to examine whether a levothyroxine interaction or levothyroxine-induced subclinical thyrotoxicosis results in increased sorafenib exposure in patients with DTC. . …
This study assessed sorafenib pharmacokinetics without and with concomitant levothyroxine to examine whether a levothyroxin …
[Levothyroxine malabsortion].
Catalina PF, Carpio D. Catalina PF, et al. Med Clin (Barc). 2015 Jul 6;145(1):46. doi: 10.1016/j.medcli.2014.09.007. Epub 2014 Nov 13. Med Clin (Barc). 2015. PMID: 25458511 Spanish. No abstract available.
Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjects: an open-label, one-sequence crossover, single-center, multiple-dose, two-part trial.
Hauge C, Breitschaft A, Hartoft-Nielsen ML, Jensen S, Bækdal TA. Hauge C, et al. Expert Opin Drug Metab Toxicol. 2021 Sep;17(9):1139-1148. doi: 10.1080/17425255.2021.1955856. Epub 2021 Aug 31. Expert Opin Drug Metab Toxicol. 2021. PMID: 34289755 Clinical Trial.
BACKGROUND: Oral semaglutide comprises the glucagon-like peptide-1 analog, semaglutide, and sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC). Levothyroxine has similar dosing conditions to oral semaglutide. This trial investigated if oral semaglutide co-administered …
BACKGROUND: Oral semaglutide comprises the glucagon-like peptide-1 analog, semaglutide, and sodium N-(8-[2-hydroxybenzoyl] amino) caprylate …
Pharmacokinetics of coadministration of levothyroxine sodium and alendronate sodium new effervescent formulation.
Bone HG, Walter MA, Hurley ME, Epstein S. Bone HG, et al. Osteoporos Int. 2017 May;28(5):1745-1752. doi: 10.1007/s00198-017-3941-3. Epub 2017 Feb 16. Osteoporos Int. 2017. PMID: 28204953 Free PMC article. Clinical Trial.
No clinically important pharmacokinetic interference of alendronate occurred between a new effervescent formulation of alendronate and levothyroxine when coadministered. The combination does not materially affect levothyroxine absorption. INTRODUCTION: Concur …
No clinically important pharmacokinetic interference of alendronate occurred between a new effervescent formulation of alendronate an …
Alternative schedules of levothyroxine administration.
Geer M, Potter DM, Ulrich H. Geer M, et al. Am J Health Syst Pharm. 2015 Mar 1;72(5):373-7. doi: 10.2146/ajhp140250. Am J Health Syst Pharm. 2015. PMID: 25694412 Review.
PURPOSE: Published evidence on bedtime versus prebreakfast administration of levothyroxine is reviewed. SUMMARY: Because levothyroxine absorption has been shown to increase when the drug is administered to patients in a fasted state, the standard recommendation is t …
PURPOSE: Published evidence on bedtime versus prebreakfast administration of levothyroxine is reviewed. SUMMARY: Because levothyro …
Levothyroxine Dosing Following Bariatric Surgery.
Gadiraju S, Lee CJ, Cooper DS. Gadiraju S, et al. Obes Surg. 2016 Oct;26(10):2538-42. doi: 10.1007/s11695-016-2314-x. Obes Surg. 2016. PMID: 27475799
Only 3 case reports and 1 case series demonstrated increased levothyroxine requirements, attributed to malabsorption. CONCLUSIONS: The loss of both fat and lean body mass may counteract malabsorptive effects from surgery, resulting in decreased postoperative levothyroxi …
Only 3 case reports and 1 case series demonstrated increased levothyroxine requirements, attributed to malabsorption. CONCLUSIONS: Th …
1,825 results